文献速递系统性红斑狼疮其他结缔组织病

2019年EULAR/ACR系统性红斑狼疮分类标准在133例未分化结缔组织病女性队列中的应用影响

Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-10-04

本研究在133例未分化结缔组织病(UCTD)女性队列中应用2019年EULAR/ACR SLE分类标准,发现17%的患者可重新分类为SLE。这些患者黏膜皮肤表现、关节炎、孤立尿检异常及高特异性抗体频率显著更高,随访中更易满足1997年ACR和SLICC标准,且新标准分类为SLE者结局评分更高。

要点

  • 17%的UCTD女性可被2019年EULAR/ACR标准重新分类为SLE。
  • 重新分类者黏膜皮肤表现、关节炎、孤立尿检异常及高特异性抗体更常见。
  • 新标准有助于早期识别进展为更严重结缔组织病的高危患者。

核心结论

  • 在UCTD女性队列中应用2019年EULAR/ACR SLE分类标准,高达17%的病例原分类受到挑战,新标准有助于早期识别进展为更严重CTD表现的高危患者。

研究设计与样本

  • 多中心队列研究,纳入133例未分化结缔组织病女性,入组时均不符合其他明确系统性结缔组织病的分类标准。

主要发现

  • 应用2019年EULAR/ACR标准后,22例(17%)符合SLE分类标准。
  • 重新分类为SLE者黏膜皮肤表现频率显著更高(23% vs 5%,P=0.007)。
  • 重新分类为SLE者关节炎频率显著更高(59% vs 17%,P<0.001)。
  • 重新分类为SLE者孤立尿检异常频率显著更高(18% vs 1%,P<0.001)。
  • 重新分类为SLE者高特异性抗体频率显著更高(50% vs 15%,P<0.001)。

关键数值与推荐

  • 随访中重新分类为SLE者更易同时满足1997年ACR修订的SLE标准和SLICC标准(18.2% vs 1.8%,P<0.001)。
  • 随访中按1997年ACR和SLICC标准诊断为SLE者,若按2019年EULAR/ACR标准分类为SLE,其结局评分更高(均值±标准差 8.3±3.7 vs 4.5±4,P<0.05)。

临床怎么用

  • 对UCTD患者应评估2019年EULAR/ACR SLE分类标准,以早期识别可能进展为SLE的高危个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to investigate the impact of applying the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in a previously described cohort of women with undifferentiated connective tissue disease (UCTD). METHODS: This study included 133 women with UCTD. At the time of inclusion into the study, none of the patients met any classification criteria for other defined systemic connective tissue disease. RESULTS: When applying the 2019 EULAR/ACR classification criteria to the cohort, 22 patients (17%) fulfilled the classification criteria for SLE. Patients classified as having SLE had significantly higher frequencies of mucocutaneous manifestations (23% versus 5%; P = 0.007), arthritis (59% versus 17%; P < 0.001), isolated urine abnormalities (18% versus 1%; P < 0.001), and highly specific antibodies (50% versus 15%; P < 0.001) compared to the other patients with UCTD. At follow-up, these patients were statistically significantly more likely to also meet the 1997 ACR revised SLE criteria and the Systemic Lupus International Collaborating Clinics (SLICC) criteria (18.2% versus 1.8%; P < 0.001) compared to the other UCTD patients. Patients who were diagnosed as having SLE according to the ACR 1997 update of the SLE revised criteria and the SLICC criteria during the follow-up scored higher on outcome measures when classified as having SLE according to the new 2019 EULAR/ACR classification criteria when compared to the other patients with UCTD (mean ± SD score 8.3 ± 3.7 versus 4.5 ± 4; P < 0.05). CONCLUSION: When applying the 2019 EULAR/ACR criteria for SLE in a cohort of patients with UCTD, we observed that in up to 17% of cases the original classification could be challenged. New implementation will help to identify earlier patients at higher risk of developing more severe CTD manifestations.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Radin M, Schreiber K, Cecchi I, et al. Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis Care Res (Hoboken). 2021. PMID: 32702197. doi:10.1002/acr.24391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。